Navigation Links
DiaSorin Furthers the Discussion on HDV, the Most Severe Form of Viral Hepatitis, in Educational Webinar

Hepatitis D virus (HDV) is a unique RNA virus that requires the hepatitis B surface antigen (HBsAg) to infect the hepatocytes. Chronic Hepatitis D is recognized as the most severe form of viral hepatitis, leading to accelerated progression of cirrhosis and hepatocellular carcinoma and a high mortality rate.

HDV infection affects an estimated 15–20 million individuals, is spread worldwide and is endemic in some regions. Moreover, HDV prevalence is increasing in many countries as a consequence of immigration from highly endemic geographic areas.

Despite the severity of hepatitis D, screening and treatment has been often neglected in part due to the lack of an effective therapy. Indeed, interferon alpha is the only anti-HDV drug approved for the treatment of chronic hepatitis D, even if its efficacy is limited and side effects can be severe. Future therapeutic options are under investigation targeting HDV entry, HBsAg secretion, and viral assembly.

Although the most aggressive infectious liver disease, hepatitis delta virus (HDV) infection may be underdiagnosed both for the unawareness or the unavailability of accurate diagnostic methods. Any hepatitis B virus (HBV) infected patient is susceptible to HDV infection for life and consequently searching for HDV should be included in HBV infected patient monitoring guidelines.

The rapid and accurate identification of HDV-infected individuals is essentially in order to optimize the patient management and to prevent the spread of the infection.

This webinar, which is sponsored by DiaSorin, will review current knowledge on virological and epidemiological aspects of HDV infection with particular attention of categories of individuals in which HDV testing should be prioritized. Speakers will identify categories of individuals at risk of acquiring HDV infection, as well as describe current and future HDV treatments.

The speakers for this event will be Dr. Valentina Svicher, an associate professor of virology at the Department of Experimental Medicine and Surgery at the University of Rome, Italy and Dr. Ana Avellon, the head of the hepatitis unit at the Spanish National Center of Microbiology, Istituto de Salud Carlos III Madrid, Spain.

LabRoots will host this webinar on November 15, 2018, beginning at 6 a.m. EDT, 3 p.m. CET. To learn more about this event, the continuing education credits offered, or to register for free, click here.

About DiaSorin Group
Headquartered in Italy and listed in the FTSE Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the IVD “Diagnostics Specialist.”

About LabRoots
LabRoots is the leading scientific social networking website, offering top scientific trending news and premier educational virtual events and webinars. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning. We have become a primary source for trending scientific news, webinars, virtual conferences and more. Offering more than articles and webcasts that go beyond the mundane and explore the latest discoveries in the world of science, LabRoots users can stay atop their field by gaining continuing education credits from a wide range of topics through their participation in the webinars and virtual events. Join for free and become part of the largest scientific learning community in the world.

Read the full story at

Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved

Related biology news :

1. AGA Research Foundation grant furthers digestive cancer research
2. Plant biology discovery furthers scientists understanding of plant growth and development
3. NuData Security Achieves Significant Milestones, Furthers Commitment to Providing Unparalleled Online Fraud Detection
4. CNBC Senior Analyst Ron Insana Moderates Discussion On Biotech Seeds At The Food Dialogues(SM): Chicago
5. A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists
6. New virus isolated from patients with severe brain infections
7. Bladder function restored in animals with severe spinal cord injury
8. Sheeps mucosa shows the way to more effective medicine for severe neurological diseases
9. Novel gene variant found in severe childhood asthma
10. Nature study discovers chromosome therapy to correct a severe chromosome defect
11. European epilepsy consortium identifies new gene for severe childhood epilepsy
Post Your Comments:
(Date:2/6/2019)... ... February 04, 2019 , ... uBiome, the leader ... insights to help individuals understand how the gut microbes may increase the risk ... individuals eat foods that contain choline and L-carnitine, such as red meat and ...
(Date:2/2/2019)... ... January 31, 2019 , ... ... organization headquartered in Morrisville, NC, providing full, customizable clinical research services across ... to support educational programs for early stage life science entrepreneurs in the ...
(Date:1/25/2019)... ... January 24, 2019 , ... GrowthZone, Inc., provider ... The report indicates membership growth in some sectors and decreasing membership among others. ... responses from over 500 association professionals across North America. , “This year’s ...
Breaking Biology News(10 mins):
(Date:1/15/2019)... ... January 15, 2019 , ... Personalized treatment plans may extend life expectancy for ... a new study published in the journal Radiology. , Kidney, or renal, tumors ... a surgical procedure in which the tumor and part of the kidney are removed. ...
(Date:1/11/2019)... ... January 11, 2019 , ... Drawing on over 22 years of software ... at 2:30pm EST will explore some of the key lessons that have driven customer ... vs. using multiple vendors, and find out how to ensure that you continue to ...
(Date:1/10/2019)... ... 2019 , ... VGI Medical was founded in 2007 based on an invention ... the market including VerteLoc, CerLoc, SiJoin and VerteLP. The VerteLoc and CerLoc systems are ... dual geometric design to limit motion of the affected spinal segment. Applying the principles ...
(Date:1/7/2019)... , ... January 07, 2019 , ... ... clinical trials of its Parkinson's Disease drug candidate, code-named "KM-819." KM-819 is ... Disease. The trial took place in South Korea. , This Phase 1 ...
Breaking Biology Technology: